The LabMyNet Phase 2 project aims to enhance access to virological diagnostic services for people living with HIV/AIDS in Myanmar.
Context
Since the Covid epidemic (2020) and the military coup (2021), Myanmar’s healthcare system has been suffering from political instability and conflicts between the junta government and its opponents. This situation, exacerbated by a Civil Disobedience Movement, has led to the collapse of public health services and a sharp decline in HIV viral load coverage. Due to international sanctions against public structures, non- governmental actors have become crucial in providing healthcare to vulnerable populations. International NGOs continue to provide antiretroviral treatment to around 52,000 patients (out of 210 000), implementing methods that reduce the need for travel. In this context, the LabMyNet Phase II project aims to support people living with HIV/AIDS.
Description
This project aims to improve access to viral load tests and virological diagnostic services, particularly in decentralized areas, by establishing 4 new viral platforms and optimizing the transport of samples between collection centers and laboratories. LabMyNet Phase II targets five key states: Yangon, Mandalay, Tanintharyi, Shan, and Kachin, and seeks to enhance the virological monitoring of people living with HIV by diversifying the range of diagnostics available. The main activities include:
- Staff training;
- Renovating laboratories and stablishing four additional platforms in Kachin, Shan, Mandalay, and Yangon states;
- Diversifying the diagnostic offering (viral hepatitis and respiratory viruses.
- Providing maintenance, additional equipment, and quality insurance.
Impact
This project is strengthening the capacity of viral load (VL) testing at eight open platforms in Myanmar, enabling the completion of 70,000 HIV VL tests per year (30% of the current national demand of test) and open VL testing to other viral infection. These eight platforms offer a diversified range of molecular diagnostics, starting with tests for Hepatitis B and SARS-CoV-2 viral loads.
